Quanta Lite Calprotectin, a new FDA-cleared assay from Inova Diagnostics Inc, San Diego, aids in the diagnosis of inflammatory bowel disease (IBD). In conjunction with other laboratory and clinical findings, the test can also help differentiate IBD from irritable bowel syndrome (IBS). The quantitative, enzyme-linked immunosorbent assay detects calprotectin levels in stool, which can provide critical information to physicians determining the appropriate care of patients suffering from gastrointestinal disorders. Accurate screening of gastrointestinal disorders can reduce unnecessary procedures and healthcare costs. For more information, visit Inova Diagnostics Inc.
Luminex Delivers New xMap IntelliFlex Systems
July 4, 2020
Luminex Corp to Acquire EraGen Biosciences Inc
July 7, 2011